|Bid||311.51 x 1000|
|Ask||315.90 x 3000|
|Day's Range||311.01 - 320.14|
|52 Week Range||182.07 - 456.23|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||129.21|
|Earnings Date||Feb 11, 2021 - Feb 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||462.94|
During the ever popular Mad Money Lightning Round Tuesday evening one caller asked Jim Cramer about DexCom . "There's competition coming from Medtronic and people need to get more careful," replied Cramer. In the updated daily bar chart of DXCM, below, we can see that the shares have been in a decline the past four months now.
Between its life-changing continuous glucose monitors, consistent growth, and sound fundamentals, DexCom (NASDAQ: DXCM) has many of the hallmarks of a good investment. It's unlikely because the stock won't be experiencing triple-digit growth anytime soon. DexCom's wearable continuous glucose monitoring (CGM) products help people with diabetes to manage their conditions without the pain of repeatedly pricking their fingers to take glucose measurements from droplets of blood.
When it comes to consistent profitability, long-term growth, large competitive moats, and innovation, medical device companies can provide better returns in the long run. In particular, DexCom (NASDAQ: DXCM), Medtronic (NYSE: MDT), and Abiomed (NASDAQ: ABMD) have beaten the NASDAQ Biotechnology Index handily over the last five years. If you had to check your blood glucose level a few times per day, you'd probably grow tired of pricking your finger to draw a drop of blood.